A pill called zuranolone has shown promising results in recent trials for the treatment of postpartum depression (PPD). The medication, which is designed to rebalance brain networks responsible for mood, arousal, behavior, and cognition, demonstrated significant improvements in depressive symptoms and was generally well tolerated, according to a new study published in The American Journal of Psychiatry. The study, funded by pharmaceutical partners Sage Therapeutics and Biogen, examined 196 mothers experiencing PPD, who were split into two groups: half received zuranolone, and half received a placebo pill, for two weeks. On day 15, all mothers showed positive developments in their depression symptoms, but those taking zuranolone had significantly better results. The improvements were still reported four and six weeks later. Side effects such as dizziness and sleepiness were experienced by only a small number of participants. The biggest unknown about the pill, according to the study authors, is its long-term effects, as well as its impact on breastfeeding. The Food and Drug Administration is expected to make a decision on zuranolone's approval by August 5. If approved, it would be the first-ever pill specifically approved for PPD. Currently, the only FDA-approved treatment for PPD is Zulresso, which is administered through an IV continuously for 60 hours. The availability of zuranolone as a once-a-day pill for two weeks could provide a more accessible and convenient treatment option for women with PPD. While the study results are promising, experts emphasize that seeking medical care and support remains crucial for anyone experiencing depression symptoms.